{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:50:49Z","timestamp":1773370249977,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T00:00:00Z","timestamp":1180137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Therapy targeted at tumour necrosis factor\u2010\u03b1 has an established role in Crohn\u2019s disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor\u2010\u03b1 properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To evaluate the efficacy and safety of lenalidomide in subjects with moderately severe active Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In a multicentre, double\u2010blind, placebo\u2010controlled parallel group study 89 subjects were randomized to lenalidomide 25\u2003mg daily, 5\u2003mg daily or placebo. Subjects were treated for 12\u2003weeks. The primary end point was a 70\u2010point reduction in Crohn\u2019s Disease Activity Index.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The overall clinical response rate was not significantly different between the three groups: lenalidomide 25\u2003mg 26%, lenalidomide 5\u2003mg 48% and placebo 39%. Lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Lenalidomide, an oral agent with antitumour necrosis factor\u2010\u03b1 properties, was not effective in active Crohn\u2019s disease in contrast to reports of benefit from thalidomide. The reasons for this lack of efficacy are speculative, other physiological activities may offset its action on inflammatory cytokines, or its antitumour necrosis factor\u2010\u03b1 action without apoptosis may be insufficient for activity in Crohn\u2019s disease.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03385.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T12:16:43Z","timestamp":1279887403000},"page":"421-430","source":"Crossref","is-referenced-by-count":28,"title":["A randomized, double\u2010blind, placebo\u2010controlled trial of lenalidomide in the treatment of moderately severe active Crohn\u2019s disease"],"prefix":"10.1111","volume":"26","author":[{"given":"J. C.","family":"MANSFIELD","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"PARKES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"HAWTHORNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"FORBES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. S. J.","family":"PROBERT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.C.","family":"PEROWNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"COOPER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"ZELDIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"MANNING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"HAWKEY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.8.913"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.12.1705"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90999-J"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.3.353"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204163261604"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.3781274.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00298.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70276-3"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70277-5"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03239.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00250-4"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070103"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2006.06.006"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1614"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03211.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.6.6"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.05.018"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF\u2010\u03b1","volume":"163","author":"Corral LG","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.196"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012292703871"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890108995961"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000215094.69869.2e"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073282"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.4065\/80.12.1549"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03385.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03385.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:14:03Z","timestamp":1697235243000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03385.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,26]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03385.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03385.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,26]]}}}